drugset / Trial / NCT06719570

A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)

NCT06719570

Phase 1 Completed 24 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to learn what happens to MK-8591A in a person's body over time. Researchers will compare what happens to MK-8591A in the body when it is given with and without food.

Timeline

Start
2024-01-23
Primary completion
2024-03-15
Completion
2024-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Doravine Unknown Oral
Subject Islatravir Other / unclassified Oral
Subject MK-8591A Unknown

Indications

No indication recorded.